



**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**  
**NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.**  
Tuesday, January 20, 2026  
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
<b>Microsoft Teams</b>  <a href="#">Join the meeting now</a>  Meeting ID: 269 897 502 335 07  Passcode: Vi3KQ9Gm  <a href="#">Download Teams</a>   <a href="#">Join on the web</a>	  +1 858-252-2734 (United States)  Phone conference ID: 170 464 566#

## AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (Upon Request)**
- III. **Old Business**
  - a. Approval of July 2025 Meeting Minutes
  - b. Approval of October 2025 Meeting Minutes
  - c. Review of Commissioner's Decision, Laxatives and Cathartics Class
- IV. **New Business**
  - a. New Products to Market to be Reviewed as Single Products
    - i. Brinsupri™ (Non-PDL)
    - ii. Orlynvah™ (Non-PDL)
    - iii. Dawnzera™ (Non-PDL)
    - iv. Legembi IQLIK™ (Central Nervous System – Alzheimer's Agents)
    - v. Wayrilz™ (Blood Modifiers – Thrombopoiesis Stimulating Proteins)
    - vi. Blujepa (Non-PDL)
    - vii. Rhapsido® (Non-PDL)
    - viii. Jascayd® (Non-PDL)
    - ix. Exxua™ (Non-PDL)
    - x. Lynkuet® (Non-PDL)
- V. **Therapeutic Classes with Recommended Changes**
  - a. Bronchodilators, Beta-Agonist
  - b. Glucocorticoids, Inhaled
  - c. Intranasal Rhinitis Agents
  - d. Macrolides/Ketolides





- e. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- f. Immunosuppressives, Oral

## VI. Consent Agenda

- a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

<ul style="list-style-type: none"><li>• Antiretrovirals, HIV/AIDS</li><li>• Antibiotics, Gastrointestinal</li><li>• Antibiotics, Inhaled</li><li>• Antibiotics, Vaginal</li><li>• Antifungals, Oral</li><li>• Antihistamines, Minimally Sedating</li><li>• Cephalosporins and Related Antibiotics</li><li>• Epinephrine, Self-Injectable</li><li>• Hepatitis B Agents</li><li>• Hepatitis C Agents</li><li>• Leukotriene Modifiers</li></ul>	<ul style="list-style-type: none"><li>• Oral Antivirals, COVID-19</li><li>• Oral Antivirals, Herpes</li><li>• Oral Antivirals, Influenza</li><li>• Oxazolidinones</li><li>• Penicillins</li><li>• Quinolones</li><li>• Chronic Obstructive Pulmonary Disease (COPD) Agents</li><li>• Sulfonamides, Folate Antagonist</li><li>• Tetracyclines</li></ul>
--	--

## VII. Adjournment

- a. Schedule of Upcoming Meetings
  - i. April 2026
  - ii. July 2026
  - iii. October 2026

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.

